Using this same patient cohort, we now address the question of how changing levels of infiltrating B and T lymphocytes may influence prostate cancer progression by analyzing levels of CD3+, CD4+, and CD20+ positive cells in the benign prostate before a cancer diagnosis and in post‐diagnosis tumor and tumor‐adjacent benign regions of prostatectomy specimens. The gene discussed is CD4; the disease is prostate carcinoma.